Key result
Ivabradine monotherapy successfully treated congenital junctional ectopic tachycardia in a premature neonate with a normal heart structure.
Why the study?
Congenital junctional ectopic tachycardia is a rare, difficult-to-treat supraventricular arrhythmia often refractory to combination antiarrhythmic therapy.
Does ivabradine monotherapy successfully treat congenital junctional ectopic tachycardia in a premature neonate?
Case Report (n=1)
Does ivabradine monotherapy successfully treat congenital junctional ectopic tachycardia in a premature neonate?
Ivabradine monotherapy may be an effective treatment for congenital junctional ectopic tachycardia in premature neonates.
May control rate in refractory congenital JET; leaves open need for controlled pediatric trials.
Congenital junctional ectopic tachycardia is a rare and special type of supraventricular arrhythmia. Junctional ectopic tachycardia is characterized by persistently elevated heart rates that may cause an impairment in cardiac function. Junctional ectopic tachycardia is considered one of the most difficult-to-treat conditions even with a combination of antiarrhythmic medications. Ivabradine is a novel antiarrhythmic medication used to decrease the heart rate in adults with angina pectoris. We report a first case of a premature neonate with a normal heart structure who developed junctional ectopic tachycardia and was subsequently treated successfully with ivabradine.
No takes yet. Share an insight, caveat, or question.
Asfour et al. (2021) conducted a case report in Congenital junctional ectopic tachycardia (n=1). Ivabradine was evaluated. Ivabradine monotherapy successfully treated congenital junctional ectopic tachycardia in a premature neonate with a normal heart structure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: